HIV treatment as prevention

population effect vs. individual protection?

G. Ippolito, G. Rezza

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

There are compelling data suggesting that antiretroviral (ARV) drugs can prevent the transmission of HIV: 1) ARV therapy reduces the intrinsic risk of transmission by cutting down the viral load in infected people; 2) ARVs may be used to prevent transmission in uninfected subjects who experienced high risk exposures. Despite these encouraging preliminary results, there are several questions that need to be answered before recommending the use of ARV among uninfected subjects: 1) the efficacy of these strategies amongst women is not yet established; 2) the cost-effectiveness of pre-exposure prophylaxis (PrEP) in the long term is undefined since PrEP efficacy may depend on adherence; 3) treating uninfected individuals may be counter-effective, as it may increase risky behavior due to the belief that ARV drugs have unlimited protective power. In conclusion, the public-health use of ARV drugs represents a new paradigm in the field of HIV prevention. However, ARV treatment cannot be considered as a substitute for other measures for preventing transmission but a complement to individual protection. In particular, post-exposure prophylaxis may be used in selected cases, whereas PrEP appears to be a highly costly method with limited public-health potential and possible safety concerns.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalAnnali di igiene : medicina preventiva e di comunità
Volume25
Issue number2
Publication statusPublished - Mar 2013

Fingerprint

HIV
Public Health
Post-Exposure Prophylaxis
Pharmaceutical Preparations
Population
Viral Load
Cost-Benefit Analysis
HIV-1
Therapeutics
Safety
Pre-Exposure Prophylaxis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

HIV treatment as prevention : population effect vs. individual protection? / Ippolito, G.; Rezza, G.

In: Annali di igiene : medicina preventiva e di comunità, Vol. 25, No. 2, 03.2013, p. 93-97.

Research output: Contribution to journalArticle

@article{14822907779846afaae38a41a93b7e92,
title = "HIV treatment as prevention: population effect vs. individual protection?",
abstract = "There are compelling data suggesting that antiretroviral (ARV) drugs can prevent the transmission of HIV: 1) ARV therapy reduces the intrinsic risk of transmission by cutting down the viral load in infected people; 2) ARVs may be used to prevent transmission in uninfected subjects who experienced high risk exposures. Despite these encouraging preliminary results, there are several questions that need to be answered before recommending the use of ARV among uninfected subjects: 1) the efficacy of these strategies amongst women is not yet established; 2) the cost-effectiveness of pre-exposure prophylaxis (PrEP) in the long term is undefined since PrEP efficacy may depend on adherence; 3) treating uninfected individuals may be counter-effective, as it may increase risky behavior due to the belief that ARV drugs have unlimited protective power. In conclusion, the public-health use of ARV drugs represents a new paradigm in the field of HIV prevention. However, ARV treatment cannot be considered as a substitute for other measures for preventing transmission but a complement to individual protection. In particular, post-exposure prophylaxis may be used in selected cases, whereas PrEP appears to be a highly costly method with limited public-health potential and possible safety concerns.",
author = "G. Ippolito and G. Rezza",
year = "2013",
month = "3",
language = "English",
volume = "25",
pages = "93--97",
journal = "Annali di igiene : medicina preventiva e di comunita",
issn = "1120-9135",
publisher = "Societa Editrice Universo",
number = "2",

}

TY - JOUR

T1 - HIV treatment as prevention

T2 - population effect vs. individual protection?

AU - Ippolito, G.

AU - Rezza, G.

PY - 2013/3

Y1 - 2013/3

N2 - There are compelling data suggesting that antiretroviral (ARV) drugs can prevent the transmission of HIV: 1) ARV therapy reduces the intrinsic risk of transmission by cutting down the viral load in infected people; 2) ARVs may be used to prevent transmission in uninfected subjects who experienced high risk exposures. Despite these encouraging preliminary results, there are several questions that need to be answered before recommending the use of ARV among uninfected subjects: 1) the efficacy of these strategies amongst women is not yet established; 2) the cost-effectiveness of pre-exposure prophylaxis (PrEP) in the long term is undefined since PrEP efficacy may depend on adherence; 3) treating uninfected individuals may be counter-effective, as it may increase risky behavior due to the belief that ARV drugs have unlimited protective power. In conclusion, the public-health use of ARV drugs represents a new paradigm in the field of HIV prevention. However, ARV treatment cannot be considered as a substitute for other measures for preventing transmission but a complement to individual protection. In particular, post-exposure prophylaxis may be used in selected cases, whereas PrEP appears to be a highly costly method with limited public-health potential and possible safety concerns.

AB - There are compelling data suggesting that antiretroviral (ARV) drugs can prevent the transmission of HIV: 1) ARV therapy reduces the intrinsic risk of transmission by cutting down the viral load in infected people; 2) ARVs may be used to prevent transmission in uninfected subjects who experienced high risk exposures. Despite these encouraging preliminary results, there are several questions that need to be answered before recommending the use of ARV among uninfected subjects: 1) the efficacy of these strategies amongst women is not yet established; 2) the cost-effectiveness of pre-exposure prophylaxis (PrEP) in the long term is undefined since PrEP efficacy may depend on adherence; 3) treating uninfected individuals may be counter-effective, as it may increase risky behavior due to the belief that ARV drugs have unlimited protective power. In conclusion, the public-health use of ARV drugs represents a new paradigm in the field of HIV prevention. However, ARV treatment cannot be considered as a substitute for other measures for preventing transmission but a complement to individual protection. In particular, post-exposure prophylaxis may be used in selected cases, whereas PrEP appears to be a highly costly method with limited public-health potential and possible safety concerns.

UR - http://www.scopus.com/inward/record.url?scp=84879286818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879286818&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 93

EP - 97

JO - Annali di igiene : medicina preventiva e di comunita

JF - Annali di igiene : medicina preventiva e di comunita

SN - 1120-9135

IS - 2

ER -